Five-Year Outcome After Continuous Flow LVAD With Full-Magnetic (HeartMate 3) Versus Hybrid Levitation System (HeartWare): A Propensity-Score Matched Study From an All-Comers Multicentre Registry.
HeartMate3
HeartWare
continuous-flow LVAD
full-magnetic levitation pump
hybrid levitation system pump
Journal
Transplant international : official journal of the European Society for Organ Transplantation
ISSN: 1432-2277
Titre abrégé: Transpl Int
Pays: Switzerland
ID NLM: 8908516
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
06
2023
accepted:
08
08
2023
medline:
21
9
2023
pubmed:
20
9
2023
entrez:
20
9
2023
Statut:
epublish
Résumé
Despite the withdrawal of the HeartWare Ventricular Assist Device (HVAD), hundreds of patients are still supported with this continuous-flow pump, and the long-term management of these patients is still under debate. This study aims to analyse 5 years survival and freedom from major adverse events in patients supported by HVAD and HeartMate3 (HM3). From 2010 to 2022, the MIRAMACS Italian Registry enrolled all-comer patients receiving a LVAD support at seven Cardiac Surgery Centres. Out of 447 LVAD implantation, 214 (47.9%) received HM3 and 233 (52.1%) received HVAD. Cox-regression analysis adjusted for major confounders showed an increased risk for mortality (HR 1.5 [1.2-1.9];
Identifiants
pubmed: 37727385
doi: 10.3389/ti.2023.11675
pii: 11675
pmc: PMC10505657
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
11675Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2023 Francica, Loforte, Attisani, Maiani, Iacovoni, Nisi, Comisso, Terzi, De Bonis, Vendramin, Boffini, Musumeci, Luciani, Rinaldi, Pacini and Onorati.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
ESC Heart Fail. 2021 Apr;8(2):1596-1603
pubmed: 33635573
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Circ Heart Fail. 2020 Mar;13(3):e006252
pubmed: 32164438
Circulation. 2021 Sep 7;144(10):763-772
pubmed: 34315231
ASAIO J. 2021 Feb 1;67(2):157-162
pubmed: 32501824
JAMA. 2022 Sep 27;328(12):1233-1242
pubmed: 36074476
ESC Heart Fail. 2022 Oct;9(5):3469-3482
pubmed: 35880515
ESC Heart Fail. 2023 Jun;10(3):1656-1665
pubmed: 36798028
Eur J Cardiothorac Surg. 2020 Jun 1;57(6):1160-1165
pubmed: 32298426
Eur J Cardiothorac Surg. 2021 Sep 11;60(3):579-587
pubmed: 33871594
Int J Surg. 2014 Dec;12(12):1495-9
pubmed: 25046131
ESC Heart Fail. 2020 Jun;7(3):908-914
pubmed: 32190985
JACC Heart Fail. 2018 Sep;6(9):792-802
pubmed: 30007559
J Heart Lung Transplant. 2020 Aug;39(8):735-750
pubmed: 32386998
ESC Heart Fail. 2021 Aug;8(4):2846-2855
pubmed: 33934564
J Heart Lung Transplant. 2015 Apr;34(4):503-8
pubmed: 25540881
Ann Thorac Surg. 2022 Apr;113(4):1172-1182
pubmed: 34087236
J Am Coll Cardiol. 2016 Jun 14;67(23):2758-2768
pubmed: 27282897
N Engl J Med. 2017 Feb 2;376(5):451-460
pubmed: 28146651
J Thorac Cardiovasc Surg. 2022 Oct;164(4):1120-1137.e2
pubmed: 35624053
JACC Heart Fail. 2015 Nov;3(11):849-56
pubmed: 26454842
Transplant Proc. 2022 May;54(4):1049-1053
pubmed: 35431097
Ann Thorac Surg. 2022 Nov;114(5):1672-1678
pubmed: 34678286
J Heart Lung Transplant. 2023 Jul;42(7):e1-e222
pubmed: 37245143
ASAIO J. 2021 Aug 1;67(8):825-826
pubmed: 34339397